TNON Stock Forecast: TENON Medical, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for TENON Medical, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 45 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores TENON Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (89): Sales and profits are climbing, and climbing faster than before.
Value (1): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TNON stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TNON, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Apr 2025 | Alliance Global Partners | Initiates | Buy | $3.00 |
| 15 Nov 2024 | Maxim Group | Maintains | Buy | — |
| 14 Aug 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 15 Apr 2024 | Benchmark | Maintains | Speculative Buy | — |
| 10 Mar 2023 | Benchmark | Reiterates | Buy | $6.00 |
| 6 Sept 2022 | Benchmark | Initiates | Speculative Buy | — |
| 21 June 2022 | Benchmark | Initiates | Speculative Buy | $6.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TNON.
This page is one stock. Monday covers all of them.
TNON appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TNON analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.4×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 81% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 63.6%
- Operating margin
- —
- Net margin
- —
Higher than 77% of US stocks
- Return on equity
- —
- Return on assets
- −55.6%
- Dividend yield
- —
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
TENON Medical, Inc. has a market value of $2.4M.
Revenue in the twelve months to 30 June 2026: $5.3M. The latest quarter grew 126.8% year on year.
Net income over the same four quarters: −$13.7M, a −257.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$12.1M.
TENON Medical, Inc. employs 26 people — $204K of revenue per employee.
Data provided by Twelve Data
TNON and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TNON’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own TENON Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TNON
What is the TNON stock price forecast for 2026-2027?
The median 12-month analyst price target for TENON Medical, Inc. is $6, with estimates ranging from $5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TNON stock a buy right now?
Of the 2 analysts covering TENON Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TENON Medical, Inc. 45 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TNON?
As at 21 Nov 2026, TENON Medical, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).
Will TNON stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $6, and Ticker Nerd's factor model ranks TENON Medical, Inc. 45 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TNON stock forecast for 2030?
No analyst covering TENON Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7 over the next 12 months.
What does TENON Medical, Inc. do?
Tenon Medical, Inc. is a medical device company focused on minimally invasive solutions for sacroiliac joint disorders and severe lower back pain. Tenon Medical develops and commercializes the Catamaran SI Joint Fusion System, along with related fixation technology, designed to stabilize and fuse the sacroiliac joint through an inferior-posterior approach using a titanium implant.
About TENON Medical, Inc.
Tenon Medical, Inc. is a medical device company focused on minimally invasive solutions for sacroiliac joint disorders and severe lower back pain. Tenon Medical develops and commercializes the Catamaran SI Joint Fusion System, along with related fixation technology, designed to stabilize and fuse the sacroiliac joint through an inferior-posterior approach using a titanium implant. Its products are used in primary SI joint procedures, revision procedures involving failed implants, and adjunct applications alongside spine fusion constructs. Based in Los Gatos, California, Tenon Medical serves the surgical spine and orthopedics market with implant systems aimed at addressing SI joint dysfunction and sacro-pelvic instability.
CEO Mr. Steven M. Foster · 26 employees · United States · https://www.tenonmed.com